New Hampshire
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
No racial disparities were found in New Hampshire for these lung cancer metrics
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in New Hampshire is 58.6 and significantly higher than the national rate of 52.8.
- New Hampshire ranks 36th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in New Hampshire improved by 15%.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer in New Hampshire is 31.4%, which is not significantly different than the national rate of 29.7%.
- New Hampshire ranks 11th among the 39 states with survival data, placing it in the above average tier.
- Over the last five years, the survival rate in New Hampshire improved by 19%.
Early Diagnosis:
- In New Hampshire, 31.1% of cases are caught at an early stage, which is significantly higher than the national rate of 28.1%.
- New Hampshire ranks 9th among the 50 states with data on early-stage diagnosis, placing it in the above average tier.
- Over the last five years, the early diagnosis rate in New Hampshire improved by 16%.
Lung Cancer Treatment
Biomarker Coverage:
- New Hampshire has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- New Hampshire ranked 4th (out of 49 states with available data) with 24.5% of cases undergoing surgery as part of the first course of treatment, which is significantly higher than the national rate of 20.7%.
- This places New Hampshire in the above average tier.
- Over the last five years, the percent of cases undergoing surgery in New Hampshire did not change significantly.
No Treatment:
- New Hampshire ranked 14th (out of 49 states with available data) with 17.8% of cases not receiving any treatment, which is significantly lower than the national rate of 21.0%.
- This places New Hampshire in the above average tier.
- Over the last five years, the percent of cases receiving no treatment in New Hampshire did not change significantly.
Screening
Screening for High Risk:
- In New Hampshire, 18.8% of those at high risk were screened, which was not significantly different than the national rate of 18.2%.
- It ranks 24th among all states, placing it in the average tier.
- Screening rates in this year’s report have been updated to correct an error in the data source and should not be compared to previous reports.
Prevention
Tobacco Use:
- The 2023 smoking rate in New Hampshire is 10.4% and not significantly different than the national rate of 11.4%.
- It ranks 14th among all states, placing it in the average tier.
Radon Exposure:
- In New Hampshire, 35.3% of radon test results were at or above the action level recommended by EPA.
- It ranks 36th among all states, placing it in the below average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 38.3 per 100,000 population among Black individuals in New Hampshire, not significantly different than the rate of 54.2 among Black individuals nationally, and significantly lower than the rate of 59.6 among white individuals in New Hampshire.
- Survival rates by race and ethnicity are not available for New Hampshire at this time. Nationally, the five-year survival rate among Black individuals is 27.1%, 9% lower than among white Americans.
- Other lung cancer rates are not available for Black individuals in New Hampshire due to too few cases over the time period to allow for accurate analysis.
Latino individuals:
- The rate of new lung cancer cases is 40.0 per 100,000 population among Latino individuals in New Hampshire, not significantly different than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 59.6 among white individuals in New Hampshire.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Latino individuals in New Hampshire due to too few cases over the time period to allow for accurate analysis.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 21.4 per 100,000 population among Asian or Pacific Islanders individuals in New Hampshire, significantly lower than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 59.6 among white individuals in New Hampshire.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Asian or Pacific Islander individuals in New Hampshire due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- Lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in New Hampshire due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in New Hampshire falling into the above average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
New Hampshire has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
New Hampshire falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 29, 2025
